Johannes Ruef

Summary

Affiliation: Red Cross Hospital Cardiology Center
Country: Germany

Publications

  1. doi request reprint One-year follow-up after implantation of the EverFlex nitinol stent in long lesions of the superficial femoral artery
    Johannes Ruef
    Red Cross Hospital Cardiovascular Center, Pfingstweidstrasse 11, Frankfurt, Germany
    Angiology 60:31-5. 2009
  2. ncbi request reprint Coronary stent thrombosis related to aspirin resistance: what are the underlying mechanisms?
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    J Interv Cardiol 19:507-9. 2006
  3. ncbi request reprint Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    Catheter Cardiovasc Interv 71:333-9. 2008
  4. ncbi request reprint Four-year results after brachytherapy for diffuse coronary in-stent restenosis: will coronary radiation therapy survive?
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    Cardiovasc Revasc Med 8:170-4. 2007
  5. ncbi request reprint Initial clinical experience with the Protégé EverFlex long self-expanding nitinol stent in the superficial femoral artery
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    J Interv Cardiol 19:544-6. 2006
  6. ncbi request reprint Endovascular interventions in iliac and infrainguinal occlusive artery disease
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    J Interv Cardiol 17:427-35. 2004
  7. ncbi request reprint Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease. (A subgroup analysis from the Ludwigshafen Risk and Cardiovascular Health Study)
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    Scand Cardiovasc J 40:274-9. 2006
  8. doi request reprint Increased restenosis rates 12 months after coronary implantation of the sirolimus-eluting YUKON-choice stent compared to the paclitaxel-eluting TAXUS Stent
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    Clin Cardiol 33:E33-8. 2010
  9. ncbi request reprint Relationship between size of myocardial infarctions assessed by delayed contrast-enhanced MRI after primary PCI, biochemical markers, and time to intervention
    Jürgen Haase
    Red Cross Hospital Cardiology Center, Frankfurt Main, Germany
    J Interv Cardiol 17:367-73. 2004
  10. ncbi request reprint Closure of guide wire-induced coronary artery perforation with a two-component fibrin glue
    Hans Störger
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    Catheter Cardiovasc Interv 70:237-40. 2007

Collaborators

Detail Information

Publications18

  1. doi request reprint One-year follow-up after implantation of the EverFlex nitinol stent in long lesions of the superficial femoral artery
    Johannes Ruef
    Red Cross Hospital Cardiovascular Center, Pfingstweidstrasse 11, Frankfurt, Germany
    Angiology 60:31-5. 2009
    ..3% (n = 26) and 93.8% (n = 30). In this first long-term evaluation, the long EverFlex nitinol stent achieves excellent clinical results after implantation into complex superficial femoral artery lesions...
  2. ncbi request reprint Coronary stent thrombosis related to aspirin resistance: what are the underlying mechanisms?
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    J Interv Cardiol 19:507-9. 2006
    ..No thrombophilic disorder was detected. Today the mechanism of aspirin resistance is mostly unknown. Further research as well as recommendations for laboratory screening and for alternative pharmacological treatment options are required...
  3. ncbi request reprint Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    Catheter Cardiovasc Interv 71:333-9. 2008
    ..To test for equivalency in unselected real-world patients with coronary lesions of various complexities, we retrospectively compared both stent designs...
  4. ncbi request reprint Four-year results after brachytherapy for diffuse coronary in-stent restenosis: will coronary radiation therapy survive?
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    Cardiovasc Revasc Med 8:170-4. 2007
    ..However, there exist limited data on the long-term effects of BT that justify its continuous use...
  5. ncbi request reprint Initial clinical experience with the Protégé EverFlex long self-expanding nitinol stent in the superficial femoral artery
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    J Interv Cardiol 19:544-6. 2006
    ..Therefore new stent devices are desirable. The present study details our initial experience with the routine use of the novel Protégé EverFlex long self-expanding nitinol stent for treatment of long SFA total occlusions or stenoses...
  6. ncbi request reprint Endovascular interventions in iliac and infrainguinal occlusive artery disease
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    J Interv Cardiol 17:427-35. 2004
    ..The increasing amount of data on successful peripheral interventions supports the necessity to adapt and reevaluate the current consensus guidelines that were put together in 2000...
  7. ncbi request reprint Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease. (A subgroup analysis from the Ludwigshafen Risk and Cardiovascular Health Study)
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    Scand Cardiovasc J 40:274-9. 2006
    ..Endothelial dysfunction and oxidative stress are involved in atherogenesis. In the search for predictors of vascular disease markers for endothelial dysfunction and oxidative stress were analyzed...
  8. doi request reprint Increased restenosis rates 12 months after coronary implantation of the sirolimus-eluting YUKON-choice stent compared to the paclitaxel-eluting TAXUS Stent
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    Clin Cardiol 33:E33-8. 2010
    ..To test for long-term equivalency in unselected real-world coronary lesions of various complexities, we retrospectively compared both stents...
  9. ncbi request reprint Relationship between size of myocardial infarctions assessed by delayed contrast-enhanced MRI after primary PCI, biochemical markers, and time to intervention
    Jürgen Haase
    Red Cross Hospital Cardiology Center, Frankfurt Main, Germany
    J Interv Cardiol 17:367-73. 2004
    ....
  10. ncbi request reprint Closure of guide wire-induced coronary artery perforation with a two-component fibrin glue
    Hans Störger
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    Catheter Cardiovasc Interv 70:237-40. 2007
    ..Therefore we consider this a novel and effective approach for closure of coronary ruptures...
  11. ncbi request reprint Ablation of atrial flutter by the femoral approach in the absence of inferior vena cava
    Jens Guenther
    Red Cross Hospital Cardiology Center, Pfingstweidstr 11, D 60316 Frankfurt, Germany
    Europace 9:1073-4. 2007
    ..Despite looping of the catheter, ablation and termination of atrial flutter were performed successfully. This is the first report of an inferior-to-superior approach for ablation of atrial flutter in the absence of the perihepatic IVC...
  12. doi request reprint The complement factor properdin induces formation of platelet-leukocyte aggregates via leukocyte activation
    Johannes Ruef
    Red Cross Hospital Cardiology Center, Frankfurt, Germany
    Platelets 19:359-64. 2008
    ..The data establish a link between the complement system and platelet-leukocyte aggregates with potential significance in atherosclerotic vascular disease...
  13. ncbi request reprint Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials
    Ulf Bertram
    Department of Cardiology, University of Heidelberg, Germany
    J Thromb Thrombolysis 14:197-203. 2002
    ..We compared combination therapy regimens consisting of GP IIb/IIIa inhibitors and thrombolytics with respect to platelet inhibition and platelet-leukocyte interactions...
  14. ncbi request reprint Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism
    Roger Kranzhofer
    Division of Cardiology, University of Heidelberg, Heidelberg, Germany
    Platelets 17:163-9. 2006
    ..However, a correlation exists to elevated eicosanoids generated by oxidative stress indicating COX-1-independent pathways for the generation of platelet activating molecules represent a potential cause for AR...
  15. ncbi request reprint Percutaneous saphenous vein graft interventions with and without distal filter wire protection
    Manfred Hofmann
    The Red Cross Hospital Cardiology Center, Frankfurt Main, Germany
    J Interv Cardiol 18:475-9. 2005
    ..Embolic protection during SVG interventions using distal balloon occlusion and aspiration has shown to reduce periprocedural complications compared to unprotected SVG interventions. A similar effect is expected from filter wires...
  16. ncbi request reprint New antithrombotic drugs on the horizon
    Johannes Ruef
    Division of Cardiology, University of Heidelberg, Bergheimer Str 58, D 69115 Heidelberg, Germany
    Expert Opin Investig Drugs 12:781-97. 2003
    ..Even though only a few of a broad array of antithrombotic agents have reached clinical testing, some hold the potential for significant improvement in efficacy and safety of anticoagulant therapy...
  17. ncbi request reprint [Interactions of statins with antithrombotic drugs]
    Johannes Ruef
    medizinische Klinik III Kardiologie, Universitat Heidelberg, Heidelberg johannes_ruef med uni heidelberg de
    Med Klin (Munich) 99:65-70. 2004
    ..So far, however, other experimental as well as clinical data do not support the hypothesis that atorvastatin or any other statin affects the antithrombotic potency of clopidogrel. The aforementioned issues will be discussed...
  18. ncbi request reprint Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates
    Martin Moser
    Division of Cardiology, University of Heidelberg, Heidelberg, Germany
    J Cardiovasc Pharmacol 41:586-92. 2003
    ..Because enzyme-dependent fibrinolysis does not appear to be involved, competitive removal of fibrinogen by the receptor antagonists is the most likely mechanism...